Viking Therapeutics
VKTX
408 hedge funds and large institutions have $3.3B invested in Viking Therapeutics in 2024 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 149 increasing their positions, 125 reducing their positions, and 88 closing their positions.
80% more call options, than puts
Call options by funds: $296M | Put options by funds: $164M
19% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 125
7% less first-time investments, than exits
New positions opened: 82 | Existing positions closed: 88
1.26% less ownership
Funds ownership: 74.87% → 73.61% (-1.3%)
3% less funds holding
Funds holding: 422 → 408 (-14)
37% less capital invested
Capital invested by funds: $5.25B → $3.3B (-$1.95B)
75% less funds holding in top 10
Funds holding in top 10: 8 → 2 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$63.2M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$58.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$49.1M |
| 4 |
Morgan Stanley
New York
|
+$41M |
| 5 |
BlackRock
New York
|
+$28.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$80.4M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$58.9M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$45.7M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$44M |
| 5 |
PA
Perceptive Advisors
New York
|
-$40.1M |
VKTX Hedge Fund Activity: Q4 2024 in Review
408 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2024, worth a combined $3.3B — down 37% from $5.25B a quarter earlier.
Sellers outnumbered buyers: 88 funds closed out of VKTX and 82 opened new positions — a net loss of 6 holders — while 125 trimmed existing stakes and 149 added.
The largest buyer was Massachusetts Financial Services, adding an estimated $63.2M. The largest seller was Perpetual Ltd, exiting entirely with an estimated $80.4M sold.
- 408 institutional investors held Viking Therapeutics (VKTX) as of Q4 2024, down from 422 in Q3 2024.
- Funds reported $3.3B of Viking Therapeutics stock for Q4 2024, down 37% quarter-over-quarter.
- 82 funds opened new Viking Therapeutics positions in Q4 2024 and 88 closed out, a net change of -6 holders.
- The largest Viking Therapeutics buyer in Q4 2024 was Massachusetts Financial Services, an estimated $63.2M added.
- The largest Viking Therapeutics seller in Q4 2024 was Perpetual Ltd, an estimated $80.4M sold.
Based on aggregated 13F filings for Q4 2024.